Safety issues and concerns of new immunomodulators in rheumatology

Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab

(2015) Penny Lovell English et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Vaccines and biologics: Table 1

(2014) Isabel Ferreira et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting

(2014) Christen Lykkegaard Andersen et al.   PLoS One

Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

(2014) Tatiana Cobo-Ibáñez et al.   RHEUMATOLOGY INTERNATIONAL

A5: Detectable Anti-Infliximab Antibodies in Children Treated with Infliximab for Rheumatic Diseases

(2014) Florence A. Aeschlimann et al.   Arthritis & Rheumatology

Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster

(2013) Kevin L. Winthrop et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions

(2013) L. Adelzadeh et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Treatment With Anti-Tumor Necrosis Factor Biologic Agents in Human T Lymphotropic Virus Type I-Positive Patients With Rheumatoid Arthritis

(2013) Kunihiko Umekita et al.   ARTHRITIS CARE & RESEARCH

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

(2012) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares

(2012) Evangelista Sagnelli et al.   Clinical & Developmental Immunology

Progressive multifocal leukoencephalopathy in autoimmune diseases

(2012) Elisabeth Palazzo et al.   JOINT BONE SPINE

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012)   LANCET

Management of rheumatic disease with comorbid HBV or HCV infection

(2012) Dimitrios Vassilopoulos et al.   Nature Reviews Rheumatology

Assessing the safety of biologic agents in patients with rheumatoid arthritis

(2012) A. Rubbert-Roth   RHEUMATOLOGY

Overview of safety of non-biologic and biologic DMARDs

(2012) E. M. Ruderman   RHEUMATOLOGY

Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease

(2012) Tauseef Ali   WORLD JOURNAL OF GASTROENTEROLOGY

Current treatment of hepatitis C-associated rheumatic diseases

(2012) Clodoveo Ferri et al.   ARTHRITIS RESEARCH & THERAPY

Epidemiological Aspects and World Distribution of HTLV-1 Infection

(2012) Antoine Gessain et al.   Frontiers in Microbiology

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy

(2011) J.-L. Lan et al.   ANNALS OF THE RHEUMATIC DISEASES

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

(2011) X. Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

(2011) Y. KOMANO et al.   JOURNAL OF RHEUMATOLOGY

Screening of tuberculosis before biologics

(2011) N. Mrozek et al.   MEDECINE ET MALADIES INFECTIEUSES

TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis

(2011) Michael A. Lane et al.   MEDICINE

Safety of biologic therapy in rheumatoid arthritis

(2011) Robert S. Woodrick et al.   Nature Reviews Rheumatology

Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis

(2011) Wassila Amari et al.   RHEUMATOLOGY

The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) J. B. Galloway et al.   RHEUMATOLOGY

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

(2011) A. M. G. Brunasso et al.   RHEUMATOLOGY

Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

(2011) Cándido Díaz-Lagares et al.   ARTHRITIS RESEARCH & THERAPY

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

(2010) I. Garcia-Doval et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

(2010) I. Solovic et al.   EUROPEAN RESPIRATORY JOURNAL

Reactivation of hepatitis B

(2010) Jay H. Hoofnagle   HEPATOLOGY

Infections in polymyositis and dermatomyositis: analysis of 192 cases

(2010) I.-J. Chen et al.   RHEUMATOLOGY

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

(2009) J D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Demyelinating events in rheumatoid arthritis after drug exposures

(2009) S. Bernatsky et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

(2009) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis

(2009) Jay R. McDonald et al.   CLINICAL INFECTIOUS DISEASES

Does the Implementation of an Interferon-γ Release Assay in Lieu of a Tuberculin Skin Test Increase Acceptance of Preventive Therapy for Latent Tuberculosis Among Healthcare Workers?

(2009) Rajiv Sahni et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

(2009) Anja Strangfeld   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: Update

(2009) Ann Corken Mackey et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Use of Tumor Necrosis Factor- -blocking Agents in Hepatitis B Virus-positive Patients: Reports of 3 Cases and Review of the Literature

(2009) S. ZINGARELLI et al.   JOURNAL OF RHEUMATOLOGY

Initiation of rheumatoid arthritis treatments and the risk of serious infections

(2009) Carlos G. Grijalva et al.   RHEUMATOLOGY

Predictors of major infections in systemic lupus erythematosus

(2009) Guillermo Ruiz-Irastorza et al.   ARTHRITIS RESEARCH & THERAPY

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action

(2008) Angelique N. Collamer et al.   ARTHRITIS AND RHEUMATISM

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

(2008)   JOURNAL OF HEPATOLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Latent Tuberculosis Diagnosis in Children by Using the QuantiFERON-TB Gold In-Tube Test

(2008) J. Lighter et al.   PEDIATRICS